Recently, Medicilon officially obtained the Good Laboratory Practice (GLP) certification certificate issued by Mexico, a member country of the OECD. In addition, we successfully passed GLP on-site inspections conducted by Hungary.

Following recent FDA and PMDA GLP audits, this achievement reaffirms that Medicilon’s preclinical research quality continues to meet the highest international standards.

🌍 Committed to Compliance Management, Empowering Global Drug Innovation
OECD GLP certification is recognized globally as the gold standard in preclinical safety evaluation for its rigor, comprehensiveness, and sustainability.

Operating under a “one-system, multi-country recognition” framework, Medicilon aligns laboratory operations with GLP requirements from:
✔️ China (NMPA)
✔️ U.S. (FDA)
✔️ Europe (EMA)
✔️ Australia (TGA)
✔️ South Korea (MFDS)

Building on NMPA, ICH, and FDA standards, we have established an advanced preclinical research platform supporting innovative therapies, including:
✔️ ADCs
✔️ PROTACs
✔️ Antibodies
✔️ Nucleic Acid Drugs

Medicilon remains dedicated to collaborating with clients worldwide through our integrated preclinical R&D service platform — helping to overcome technical barriers and accelerate the development of innovative medicine.

#Medicilon #GLP #OECD #PreclinicalResearch #QualityFirst #InnovationDriven #DrugDiscovery #GlobalCRO